Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Brian Hilberdink says he wasn’t looking for a new job when he got the call from Boehringer Ingelheim to join up as their new ...

The two stocks have been trending in different directions for months. Here's what that says about the broader market.

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...

NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...

If you believed everything you read on social media, you’d think HHS Secretary Robert F. Kennedy Jr. had issued a sweeping ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...